Discovery Laboratories Inc (DSCO)

1.77
0.03 1.61
NASDAQ : Health Care
Prev Close 1.80
Open 1.82
Day Low/High 1.70 / 1.82
52 Wk Low/High 1.42 / 8.12
Volume 12.44K
Avg Volume 94.60K
Exchange NASDAQ
Shares Outstanding 8.19M
Market Cap 31.62M
EPS -7.25
P/E Ratio N/A
Div & Yield N.A. (N.A)
Overnight News on TheStreet.com: Aug. 14

Overnight News on TheStreet.com: Aug. 14

A sampling of stories published in the early morning hours Friday that you may have missed.

Discovery Labs Dumps CEO Capetola

Ineptitude and mismanagement were the hallmarks of Robert Capetola, who has left as CEO of beleaguered drug company Discovery Labs.

Discovery Labs CEO Resigns; Chairman Takes Over

Discovery Labs says president, founding CEO Robert Capetola resigns; Amick named interim CEO

Biotech Stock Mailbag: Onyx, Savient

This week, readers weigh in on Onyx Pharma's fund-raising, Savient's gout treatment and Spectrum's Fusilev.

Biotech Stock Mailbag: Discovery Labs

Readers sound off on Discovery Labs, Micromet and BioDelivery.

Biotech Stock Mailbag: Immunomedics

Biotech Stock Mailbag: Immunomedics

Readers seek insight on Immunomedics, Discovery Labs and AMAG Pharmaceuticals.

Dendreon Investors, Be Patient

Dendreon's Provenge data is certainly positive, but investors must consider regulatory and manufacturing concerns.

Discovery Laboratories Gets FDA Letter On Surfaxin

Discovery Laboratories receives another FDA request on the Surfaxin drug application

Biotech Stock Mailbag: Panacos

Biotech Stock Mailbag: Panacos

Panacos is worth more than 12 cents -- and is worth hanging on to.

For Biotech Stocks, '09 May Be Touch and Go

Market and economic turmoil and a new president cloud the forecast for the biotech sector, but investors can make some educated guesses.

For AMAG, FDA Delay Only a Flesh Wound

Shares are down on a delay in the approval decision for an iron replacement drug, but the news could have been far worse.

Biotech Mailbag: All About Alnylam

Biotech Mailbag: All About Alnylam

The stock hasn't been this low since July 2007, but lung drug data could set it up for a rebound.

Insiders Bet on Discovery Drug Approval

Insiders Bet on Discovery Drug Approval

This biotech is a gamble, but the catalysts and timeline are established.

Health Winners & Losers: Vertex

Health Winners & Losers: Vertex

The Nasdaq and Amex biotechnology indices are up 1.2% and 0.7%, respectively.

Biotech-Stock Mailbag: Genentech

Biotech-Stock Mailbag: Genentech

If Roche is serious about buying the company, it will need to do much better than $89 a share.

Health Winners & Losers: Gilead

Gilead climbs on several bullish analyst notes.

Discovery Labs: More Delays for Surfaxin

The stock sinks after the company reveals it will not respond as swiftly as it thought to the FDA's concerns about Surfaxin.

A Quiet Medicines Co. Raises Questions

The CEO last week disclosed a regulatory hiccup in its application for Cleviprex, months after the FDA first informed the company of a delay.

Monday's Winners & Losers: Yahoo!

Shares fall 15% after the company's buyout by Microsoft falls apart.

Monday's Health Winners & Losers

Albany Molecular climbs on a rise in profits.

Discovery Labs Holds Out Hope for Surfaxin

The stock Monday regains some of its sharp Friday losses on the company's positive response to FDA delays. But is the reaction overly optimistic?

Friday's Winners & Losers: Yahoo!

Shares rise 6.9% on more merger rumors.

Friday's Health Winners & Losers

Discovery Labs falls on another regulatory delay for its Surflaxin.

FDA Approval Delay Sinks Discovery Labs

Surfaxin receives an approvable letter, but the additional delays that accompany it send shares plummeting in premarket trading.

Wednesday's Winners & Losers: Buffalo Wild Wings

Shares soar 22% after the company announces in-line earnings.

Wednesday's Health Winners & Losers

BioMarin climbs higher after swinging to a profit and beating Wall Street estimates for the first quarter.

Discovery Labs Awaits FDA Word on Surfaxin

A regulatory decision on the lung treatment could come May 1, but even with approval the biotech will have to work for every bit of upside.

FDA Backlog Leaves Biotech Stocks in Limbo

A lack of resources leads the agency to push back drug approval deadlines, adding murkiness to an already tricky sector.

Monday's Health Winners & Losers

Possis Medical soars after Bayer agrees to buy the company for $361 million.

Friday's Winners and Losers: Smith & Wesson

The gun-maker plummets 28.6% after a triple analyst downgrade.